00:43 , Jul 3, 2014 |  BC Extra  |  Financial News

Viking files for IPO

Viking Therapeutics Inc. (San Diego, Calif.) filed to raise up to $57.5 million in an IPO on NASDAQ underwritten by Oppenheimer; Roth Capital Partners; Craig-Hallum Capital; MLV; and Summer Street. In May, Ligand Pharmaceuticals Inc....
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Ligand, Viking Therapeutics deal

Ligand granted Viking Therapeutics exclusive, worldwide rights to five therapeutic programs, including two clinical-stage compounds. The deal includes VK0612 (formerly MB07803 ), a fructose 1,6-bisphosphatase inhibitor in Phase II testing to treat Type II diabetes;...
00:11 , May 23, 2014 |  BC Extra  |  Company News

Ligand licenses five programs to Viking

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Viking Therapeutics Inc. (San Diego, Calif.) exclusive, worldwide rights to five therapeutic programs, including two clinical-stage compounds, one preclinical compound, and two portfolios of preclinical compounds. The clinical programs are:...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Company News

Metabasis endocrine, metabolic, infectious news

Metabasis hired Merriman Curhan Ford to assist in exploring and evaluating strategic alternatives. The biotech's MB07803 is in Phase II testing for Type II diabetes. Metabasis restructured and reduced headcount in May to evaluate alternatives...
07:00 , Jul 6, 2009 |  BioCentury  |  Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

Metabasis endocrine, metabolic news

Metabasis reduced headcount for the third time in seven months to conserve cash. The company will reduce headcount by 45 (87%) to seven. The remaining employees will assist the company's Board in evaluating and implementing...
07:00 , Apr 6, 2009 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/08 1/9/09 Array BioPharma Inc. (NASDAQ:ARRY) 10% to ~350 $82.6 0.77 12/31/08 $53.9 (6-mo op loss ended 12/31/08) Seeking...
07:00 , Mar 30, 2009 |  BC Week In Review  |  Clinical News

MB07803: Phase Ib data

Data from a double-blind, U.S. Phase Ib trial in 42 patients showed that 200 and 400 mg MB07803 twice daily met the efficacy endpoint of a significant reduction from baseline in 6-hour FPG as determined...
08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

Metabasis metabolic, endocrine news

Metabasis Therapeutics Inc. (NASDAQ:MBRX), La Jolla, Calif.   Business: Metabolic, Endocrine   Metabasis restructured and reduced headcount for the second time in three months, cutting headcount by 38 (43%) to about 50 with most of...
08:00 , Jan 5, 2009 |  BioCentury  |  Finance

2009 Financial Markets Preview: Weathering (nuclear)winter

By Steve Edelson & Mike Ward Senior Editors The burning question going into 2009 is how to survive it. It's unclear whether the capital markets will even be relevant, and if so, how. Financing activity...